JPWO2020123663A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020123663A5
JPWO2020123663A5 JP2021533154A JP2021533154A JPWO2020123663A5 JP WO2020123663 A5 JPWO2020123663 A5 JP WO2020123663A5 JP 2021533154 A JP2021533154 A JP 2021533154A JP 2021533154 A JP2021533154 A JP 2021533154A JP WO2020123663 A5 JPWO2020123663 A5 JP WO2020123663A5
Authority
JP
Japan
Prior art keywords
composition
smad4
subject
glial
under conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511568A (ja
JP7518547B2 (ja
JP2022511568A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065742 external-priority patent/WO2020123663A1/en
Publication of JP2022511568A publication Critical patent/JP2022511568A/ja
Publication of JPWO2020123663A5 publication Critical patent/JPWO2020123663A5/ja
Publication of JP2022511568A5 publication Critical patent/JP2022511568A5/ja
Priority to JP2024104638A priority Critical patent/JP2024129091A/ja
Application granted granted Critical
Publication of JP7518547B2 publication Critical patent/JP7518547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533154A 2018-12-11 2019-12-11 統合失調症及び他の神経精神障害の治療方法 Active JP7518547B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024104638A JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778145P 2018-12-11 2018-12-11
US62/778,145 2018-12-11
PCT/US2019/065742 WO2020123663A1 (en) 2018-12-11 2019-12-11 Methods of treating schizophrenia and other neuropsychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024104638A Division JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Publications (4)

Publication Number Publication Date
JP2022511568A JP2022511568A (ja) 2022-01-31
JPWO2020123663A5 true JPWO2020123663A5 (https=) 2022-12-15
JP2022511568A5 JP2022511568A5 (https=) 2022-12-15
JP7518547B2 JP7518547B2 (ja) 2024-07-18

Family

ID=69160318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533154A Active JP7518547B2 (ja) 2018-12-11 2019-12-11 統合失調症及び他の神経精神障害の治療方法
JP2024104638A Pending JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024104638A Pending JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Country Status (7)

Country Link
US (1) US20220025379A1 (https=)
EP (1) EP3894556A1 (https=)
JP (2) JP7518547B2 (https=)
CN (2) CN119925614A (https=)
AU (1) AU2019396450B2 (https=)
CA (1) CA3122289A1 (https=)
WO (1) WO2020123663A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110011658A (ko) 2008-05-08 2011-02-08 유니버시티 오브 로체스터 최적화된 세포 제제에 의한 수초 질환의 치료
EP2954046B1 (en) 2013-02-06 2025-10-15 University Of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
JP7457505B2 (ja) 2017-05-10 2024-03-28 ユニバーシティー オブ ロチェスター 神経精神障害を処置する方法
WO2019246262A2 (en) 2018-06-21 2019-12-26 University Of Rochester Methods of treating or inhibiting onset of huntington's disease
CN116350758B (zh) * 2023-03-16 2024-08-06 郑州大学 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
US6013787A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad4 expression
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
AU2003260370B2 (en) 2002-08-05 2008-05-22 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
KR100750788B1 (ko) 2003-09-18 2007-08-20 아이시스 파마수티컬즈 인코포레이티드 eIF4E 발현의 조정
AU2005252663B2 (en) 2004-06-03 2011-07-07 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US7128264B2 (en) 2004-07-23 2006-10-31 Symbol Technologies, Inc: Electro-optical reader with improved performance in high intensity ambient light
JP4428296B2 (ja) 2005-06-10 2010-03-10 セイコーエプソン株式会社 表示パネルモジュールおよび表示装置
US9962558B2 (en) * 2005-08-05 2018-05-08 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
BRPI0619794B8 (pt) 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US10047346B2 (en) 2008-08-08 2018-08-14 Mayo Foundation For Medical Education And Research Method of treating heart tissue using induced pluripotent stem cells
US20120276070A1 (en) 2009-11-17 2012-11-01 Vitro Diagnositics, Inc. Induced Pluripotent Stem Cells and Related Methods
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
EP2723861A4 (en) * 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
PT2773748T (pt) * 2011-11-04 2020-03-26 Memorial Sloan Kettering Cancer Center Neurónios dopaminérgicos (da) do mesencéfalo para enxerto
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2016115558A2 (en) 2015-01-16 2016-07-21 Bruno Doiron Compositions and methods for creating pancreatic cancer animal model

Similar Documents

Publication Publication Date Title
Huang et al. Inhibition of microRNA-210 suppresses pro-inflammatory response and reduces acute brain injury of ischemic stroke in mice
Schaller et al. Cerebral ischemic preconditioning: an experimental phenomenon or a clinical important entity of stroke prevention?
Kim et al. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
Fusco et al. Preventative effect of repeated nasal applications of capsaicin in cluster headache
Zhang et al. Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons
JP2021529169A5 (https=)
Nakada et al. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly (isobutylcyanoacrylate) nanoparticles after intravenous administration in mice
CA2826836A1 (en) Antisense oligonucleotides
ME02850B (me) Sastavi i metode za inhibiranje ekspresije alas1 gena
US20250051766A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
JPWO2020123663A5 (https=)
Ammon-Treiber et al. Effects of opioid antagonists and morphine in a hippocampal hypoxia/hypoglycemia model
CN107405315A (zh) 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达
JPWO2020206350A5 (https=)
Lu et al. Astrocytic c-Jun N-terminal kinase-histone deacetylase-2 cascade contributes to glutamate transporter-1 decrease and mechanical allodynia following peripheral nerve injury in rats
RU2020125769A (ru) Олигонуклеотиды для модуляции экспрессии tmem106b
Fang et al. Silencing miR-155–5p alleviates hippocampal damage in kainic acid-induced epileptic rats via the Dusp14/MAPK pathway
US10947538B2 (en) Allele-specific gene suppression
KR20240099216A (ko) 슈반 세포로의 표적화 전달을 위한 설계자 세포외 소낭
JPWO2019246112A5 (https=)
WO2026026776A1 (zh) 抑制APP基因表达的siRNA及其缀合物和应用
US20050075282A1 (en) Materials and methods for inhibiting the development of epilepsy
WO2023158955A3 (en) 3α-OH-5β-PREGNAN-20-ONE COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS
WO2023288240A8 (en) Antisense oligonucleotide (aso) gene inhibition and treatment
JP2021527649A5 (https=)